Core Viewpoint - BioArctic AB's partner Eisai has achieved the first sales milestone for Leqembi, with sales reaching €200 million in Eisai's fiscal year 2024, resulting in a €10 million payment to BioArctic [1]. Company Overview - BioArctic AB is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including Alzheimer's disease [9]. - The company developed Leqembi (lecanemab), the first drug proven to slow the progression of early Alzheimer's disease [9]. - BioArctic has a collaboration with Eisai that began in 2005, which includes agreements for the development and commercialization of lecanemab [7]. Product Information - Leqembi is a humanized IgG1 monoclonal antibody targeting amyloid-beta aggregates, approved in multiple countries for treating mild cognitive impairment and mild Alzheimer's dementia [3][4]. - A supplemental Biologics License Application for less frequent intravenous maintenance dosing was approved by the FDA in January 2025 [5]. - Eisai's ongoing Phase 3 clinical study (AHEAD 3-45) is investigating lecanemab in individuals with preclinical Alzheimer's disease [6]. Financial Milestones - The sales milestone of €200 million entitles BioArctic to a €10 million payment, highlighting the financial success of Leqembi [1][8]. - BioArctic is entitled to payments related to regulatory approvals, sales milestones, and royalties on global sales of lecanemab [8].
Leqembi® sales reaches €200 million - first sales milestone achieved